Latanoprost 1 A Pharma (Latanoprost)

• Latanoprost is a prostaglandin analog used to lower intra‑ocular pressure in glaucoma‑related conditions.
• Open-angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage.
• Ocular hypertension: lowers eye pressure to prevent development of glaucoma.
• Secondary glaucoma (e.g., steroid‑induced): helps control pressure when other agents are insufficient.

• Latanoprost binds to prostaglandin F‑type receptors in the ciliary body, enhancing uveoscleral outflow of aqueous humor. This increased drainage lowers intra‑ocular pressure, helping to protect the optic nerve and preserve visual function.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects

• Eye redness: mild conjunctival hyperemia.
• Increased eyelash growth: longer, thicker lashes.
• Iris darkening: gradual brownish pigmentation.
• Eye irritation: stinging or burning sensation.
• Blurred vision: transient visual disturbance.
• Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects

• Severe allergic reaction: swelling, rash, or difficulty breathing.
• Uveitis: inflammation of the uveal tract.
• Corneal edema: swelling of the cornea affecting clarity.
• Vision loss: sudden decrease in visual acuity.
• Paradoxical IOP increase: unexpected rise in eye pressure.
• Ocular infection: signs of bacterial or fungal involvement.

• Before initiating therapy, patients should be evaluated for ocular health and potential risk factors.
• Monitor IOP: measure intra‑ocular pressure regularly to assess efficacy.
• Assess ocular surface: watch for irritation or inflammation.
• Avoid use in active eye infection: defer treatment until infection resolves.
• Do not combine with other prostaglandin analogs: risk of additive hypotony.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid)

• Concomitant use with other prostaglandin analogs: may cause excessive IOP lowering.
• Use with ocular NSAIDs: increased risk of corneal complications.
• Systemic carbonic anhydrase inhibitors: may reduce latanoprost efficacy.

Moderate Interactions (Monitor Closely)

• Beta‑blocker eye drops: additive IOP reduction may require monitoring.
• Alpha‑agonist eye drops: potential alteration of therapeutic effect.
• Topical corticosteroids: may diminish response to latanoprost.